Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06211062 · ClinicalTrials.gov registry record · Phase 2
The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
A Phase 2 study of IBS - Irritable Bowel Syndrome and ME/CFS, sponsored by Nova Southeastern University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06211062 is a Phase 2 study of IBS - Irritable Bowel Syndrome and ME/CFS that is actively recruiting participants, run by Nova Southeastern University. The registered enrollment target is 100 participants, above the 66-participant average among 6 other IBS - Irritable Bowel Syndrome trials with a reported enrollment target (52% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06211062, a Phase 2 study of IBS - Irritable Bowel Syndrome and ME/CFS, is actively recruiting participants, sponsored by Nova Southeastern University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical study aims to evaluate the use of i3.1 probiotic in participants who meet the Institute of Medicine (Canadian Consensus Criteria) case definition for ME/CFS and who may or may not be diagnosed with irritable bowel syndrome (IBS). The main questions it aims to answer are: * how effective is the usage of the i3.1 probiotic to reduce gastrointestinal (GI) inflammation and normalize the GI and systemic/brain interface? * how well is it working on IBS severity? The study sample is 100 male and female participants aged 45 to 70 years with ME/CFS (per the Canadian Consensus Criteria); one-half of the participants will have co-morbid IBS (per Rome IV criteria). Participants will receive an i3.1 or a placebo and be assessed at baseline, at eight weeks, and at 12 weeks (four weeks post-treatment completion).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Floradapt Intensive GI
Study Locations (1)
Florida
- Institute for Neuroimmune Medicine - Fort Lauderdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-12-20 |
| Est. Completion | 2026-02-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06211062
The ClinicalTrials.gov registry entry for NCT06211062 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 66-participant average among 6 other IBS - Irritable Bowel Syndrome trials with a reported enrollment target (52% higher). The listed sponsor is Nova Southeastern University, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with IBS - Irritable Bowel Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06211062 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06211062 about?
NCT06211062 is a clinical study titled "The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". This clinical study aims to evaluate the use of i3.1 probiotic in participants who meet the Institute of Medicine (Canadian Consensus Criteria) case definition for ME/CFS and who may or may not be diagnosed with irritable bowel syndrome (IBS). The main questions it aims to answer are: * how effecti...
What is the current status of trial NCT06211062?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2022-12-20. Estimated completion is 2026-02-24.
What conditions does trial NCT06211062 study?
This clinical trial studies the following conditions: IBS - Irritable Bowel Syndrome, ME/CFS.
What interventions are being tested in trial NCT06211062?
The interventions under investigation include: Placebo (OTHER), Floradapt Intensive GI (DRUG).
Who is sponsoring clinical trial NCT06211062?
This trial is sponsored by Nova Southeastern University, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06211062 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IBS - Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease
RECRUITING
-
ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects
RECRUITING
-
Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator
RECRUITING · Early Phase 1
-
Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)
ACTIVE NOT RECRUITING · NA
-
Relaxation Music for Chronic Pain
ACTIVE NOT RECRUITING · NA
-
Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.